ABT Molecular Imaging, Inc.
Formerly Advanced Biomarker Technologies LLC
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2012 | $6 M | No. 3 | $2 to $10 million | equity | SEC | |
| Jun 2011 | $4 M | No. 2 | $2 to $10 million | equity | SEC | |
| Sep 2009 | $6 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
ABT Molecular Imaging, Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Sep 2012).
SEC Form D (revenue range) · Sep 2012
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2012
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of ABT Molecular Imaging, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 5 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Robert A Vincill | Executive officer | Sep 2012 |
| Thomas E Welch | Executive officer | Sep 2012 |
| Vincill A. Robert | Executive officer | Jun 2011 |
| Welch E. Thomas | Executive officer | Jun 2011 |
| Lynda Nutt | Executive officer | Oct 2009 |
| Ronald Nutt | Executive officer | Oct 2009 |
| Bengt A Langstrom | Director | Sep 2012 |
| Dennis Dougherty | Director | Sep 2012 |
| Ronald Nutt | Director | Sep 2012 |
| Rurik Gerard Vandevenne | Director | Sep 2012 |
| Thomas E Welch | Director | Sep 2012 |
| Dennis A. Dougherty | Director | Jun 2011 |
| Welch E. Thomas | Director | Jun 2011 |
| William A. McInnes | Director | Jun 2011 |
| Henry Wagner | Director | Oct 2009 |
| William McInnes | Director | Oct 2009 |